Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's

Aspen Pharmacare Holdings Limited's (JSE:APN) dividend will be increasing from last year's payment of the same period to ZAR3.26 on 26th of September. Based on this payment, the dividend yield for the company will be 2.3%, which is fairly typical for the industry.

View our latest analysis for Aspen Pharmacare Holdings

Advertisement

Aspen Pharmacare Holdings' Dividend Is Well Covered By Earnings

We aren't too impressed by dividend yields unless they can be sustained over time. However, prior to this announcement, Aspen Pharmacare Holdings' dividend was comfortably covered by both cash flow and earnings. As a result, a large proportion of what it earned was being reinvested back into the business.

Looking forward, earnings per share is forecast to rise by 18.6% over the next year. If the dividend continues on this path, the payout ratio could be 19% by next year, which we think can be pretty sustainable going forward.

historic-dividend
JSE:APN Historic Dividend September 21st 2022

Dividend Volatility

The company has a long dividend track record, but it doesn't look great with cuts in the past. Since 2012, the dividend has gone from ZAR1.57 total annually to ZAR3.26. This implies that the company grew its distributions at a yearly rate of about 7.6% over that duration. A reasonable rate of dividend growth is good to see, but we're wary that the dividend history is not as solid as we'd like, having been cut at least once.

We Could See Aspen Pharmacare Holdings' Dividend Growing

With a relatively unstable dividend, it's even more important to see if earnings per share is growing. Aspen Pharmacare Holdings has seen EPS rising for the last five years, at 5.3% per annum. A low payout ratio and decent growth suggests that the company is reinvesting well, and it also has plenty of room to increase the dividend over time.

In Summary

Overall, this is a reasonable dividend, and it being raised is an added bonus. The dividend has been at reasonable levels historically, but that hasn't translated into a consistent payment. This looks like it could be a good dividend stock going forward, but we would note that the payout ratio has been at higher levels in the past so it could happen again.

It's important to note that companies having a consistent dividend policy will generate greater investor confidence than those having an erratic one. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. Companies that are growing earnings tend to be the best dividend stocks over the long term. See what the 4 analysts we track are forecasting for Aspen Pharmacare Holdings for free with public analyst estimates for the company. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About JSE:APN

Aspen Pharmacare Holdings

Manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia.

Flawless balance sheet and undervalued.

Advertisement

Weekly Picks

CE
Ceazar
GOAI logo
Ceazar on Eva Live ·

This small cap is building the AI workforce of the future

Fair Value:US$7.4351.3% undervalued
82 users have followed this narrative
0 users have commented on this narrative
17 users have liked this narrative
TR
tripledub
LULU logo
tripledub on lululemon athletica ·

Lululemon Got Boring Right About the Time It Got Cheap. That's Usually the Point

Fair Value:US$22042.2% undervalued
26 users have followed this narrative
6 users have commented on this narrative
28 users have liked this narrative
WO
woodworthfund
KHC logo
woodworthfund on Kraft Heinz ·

Kraft Heinz (KHC): Less Drama, More Ketchup

Fair Value:US$3532.0% undervalued
9 users have followed this narrative
0 users have commented on this narrative
2 users have liked this narrative
CA
Canderous
TAL logo
Canderous on PetroTal ·

Beyond 2026, Beyond a Double

Fair Value:CA$1.8166.9% undervalued
29 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative

Updated Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7444.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DO
Double_Bubbler
MDAI logo
Double_Bubbler on Spectral AI ·

Spectral AI: First of Its Kind Automated Wound Healing Prediction

Fair Value:US$546.4% undervalued
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RO
Robbo
KOV logo
Robbo on Korvest ·

Korvest: A Quiet Australian Industrial with Data Centre Exposure

Fair Value:AU$16.33.1% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8590.4% undervalued
114 users have followed this narrative
2 users have commented on this narrative
31 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$268.6119.8% undervalued
1192 users have followed this narrative
7 users have commented on this narrative
34 users have liked this narrative
TR
tripledub
LULU logo
tripledub on lululemon athletica ·

Lululemon Got Boring Right About the Time It Got Cheap. That's Usually the Point

Fair Value:US$22042.2% undervalued
26 users have followed this narrative
6 users have commented on this narrative
28 users have liked this narrative